Literature DB >> 21208878

Seventh edition of the cancer staging manual and stage grouping of lung cancer: quick reference chart and diagrams.

Omar Lababede1, Moulay Meziane, Thomas Rice.   

Abstract

Lung cancer remains the most common cause of cancer-related death in the United States. TNM staging, which is an important guide to the prognosis and treatment of lung cancer, has been revised recently. In this article, we propose a quick reference chart and diagrams that consolidate TNM staging information in a simple format. The current classification of lymph node stations and zones is illustrated as well.

Entities:  

Mesh:

Year:  2011        PMID: 21208878     DOI: 10.1378/chest.10-1099

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  28 in total

Review 1.  The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome.

Authors:  Romain Remark; Christian Becker; Jorge E Gomez; Diane Damotte; Marie-Caroline Dieu-Nosjean; Catherine Sautès-Fridman; Wolf-Herman Fridman; Charles A Powell; Nasser K Altorki; Miriam Merad; Sacha Gnjatic
Journal:  Am J Respir Crit Care Med       Date:  2015-02-15       Impact factor: 21.405

2.  Safety creatinine clearance level for platinum chemotherapy in lung cancer patients.

Authors:  Gen Ohara; Kunihiko Miyazaki; Koichi Kurishima; Katsunori Kagohashi; Hiroichi Ishikawa; Hiroaki Satoh; Nobuyuki Hizawa
Journal:  Oncol Lett       Date:  2011-11-16       Impact factor: 2.967

3.  The Eighth Edition of TNM Staging of Lung Cancer: Reference Chart and Diagrams.

Authors:  Omar Lababede; Moulay A Meziane
Journal:  Oncologist       Date:  2018-04-12

4.  Correlation of EGFR mutation and histological subtype according to the IASLC/ATS/ERS classification of lung adenocarcinoma.

Authors:  Zhen Chen; Xiaoyan Liu; Jing Zhao; Hanjin Yang; Xiaodong Teng
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

5.  Expression of peroxisome proliferator activated receptor-gamma (PPAR-γ) in human non-small cell lung carcinoma: correlation with clinicopathological parameters, proliferation and apoptosis related molecules and patients' survival.

Authors:  Costantinos Giaginis; Ekaterini Politi; Paraskevi Alexandrou; John Sfiniadakis; Gregory Kouraklis; Stamatios Theocharis
Journal:  Pathol Oncol Res       Date:  2012-03-18       Impact factor: 3.201

6.  Nomogram prediction for the survival of the patients with small cell lung cancer.

Authors:  Hui Pan; Xiaoshun Shi; Dakai Xiao; Jiaxi He; Yalei Zhang; Wenhua Liang; Zhi Zhao; Zhihua Guo; Xusen Zou; Jinxin Zhang; Jianxing He
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

7.  Age-dependent decline in renal function in patients with lung cancer.

Authors:  Gen Ohara; Koichi Kurishima; Kensuke Nakazawa; Mio Kawaguchi; Katsunori Kagohashi; Hiroichi Ishikawa; Nobuyuki Hizawa; Hiroaki Satoh
Journal:  Oncol Lett       Date:  2012-04-05       Impact factor: 2.967

8.  Hu-antigen receptor (HuR) and cyclooxygenase-2 (COX-2) expression in human non-small-cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival.

Authors:  Constantinos Giaginis; Paraskevi Alexandrou; Nikolaos Tsoukalas; Ioannis Sfiniadakis; Nikolaos Kavantzas; Emmanuel Agapitos; Efstratios Patsouris; Stamatios Theocharis
Journal:  Tumour Biol       Date:  2014-09-25

9.  Application of conditional probability analysis to distant metastases from lung cancer.

Authors:  Akihiro Oikawa; Hideto Takahashi; Hiroichi Ishikawa; Koichi Kurishima; Katsunori Kagohashi; Hiroaki Satoh
Journal:  Oncol Lett       Date:  2011-12-23       Impact factor: 2.967

10.  Prognostic and predictive role of ERCC1 protein expression in locally advanced stage III non-small cell lung cancer.

Authors:  Lamiss Mohamed Sad; Samar Galal Younis; Mohamed Mosad Elity
Journal:  Med Oncol       Date:  2014-06-17       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.